BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Roche

Status: Completed

Conditions: Ovarian Cancer

Treatments: Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02393898

ML29515

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy in the frontline treatment of ovarian cancer in participants 70 years of age and older in routine clinical practice in Belgium. Bevacizumab will be used in combination with carboplatin/paclitaxel followed by bevacizumab as maintenance in accordance with the Summary of Product Characteristics (SmPC).

Enrollment: 76 patients

Sex: Female

Ages: 70+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 70 years and older
• No treatment with any other investigational agent within 28 days or 2 half-lives (whichever is longer) prior to enrollment

Exclusion criteria

• Contraindications, warnings, and precautions for bevacizumab

Trial design

76 participants in 1 patient group

Elderly Participants with Ovarian Cancer

Description:

Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.

Treatment:

Drug: Carboplatin

Drug: Bevacizumab

Drug: Paclitaxel